drugset / Trial / NCT00645203

Safety and Efficacy Study of Cefdinir Oral Suspension, in Pediatric Subjects to Treat Acute Otitis Media

NCT00645203

Phase 2/3 Completed 447 enrolled Abbott
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of cefdinir oral suspension in children between 6 months and 4 years of age, with acute otitis media, who are at risk of persistent or recurrent otitis media.

Timeline

Start
2002-07
Primary completion
2003-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject cefdinir Other / unclassified 25 mg/kg Oral

Indications